Results 61 to 70 of about 1,772,527 (156)

A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients

open access: yesFrontiers in Oncology
This study aimed to investigate the efficacy, safety and prognostic value of measurable residual disease (MRD) in unfit AML patients treated with long-course venetoclax combined with hypomethylating agents, so as to provide evidence for optimizing ...
Chen Cao   +8 more
doaj   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

open access: yesAndrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis   +3 more
wiley   +1 more source

Oral Azacitidine Maintenance After CPX‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia

open access: yes
American Journal of Hematology, EarlyView.
Caroline Fileni   +18 more
wiley   +1 more source

Differential Sperm DNA Methylation Profiles in Healthy Men With High Versus Low Adherence to the Mediterranean Diet in the Led‐Fertyl Study

open access: yesAndrology, EarlyView.
ABSTRACT Background Diet is known to play an essential role not only in sperm quality but also in offspring health, likely mediated through the sperm epigenome. Moreover, one of the main components of the Mediterranean diet (MedDiet) (i.e., nuts) have shown to impact sperm DNA methylation patterns.
Rashmi Agarwal   +10 more
wiley   +1 more source

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study

open access: yesHematology
Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML ...
Fei Xin   +3 more
doaj   +1 more source

Hypomethylating Agents and Epigenetic Biomarkers: Reprogramming Methylation Patterns in Cancer Therapy. [PDF]

open access: yes
A total of 1,487 records were identified, of which 42 studies met the inclusion criteria. Hypomethylating agents, particularly azacitidine and decitabine, demonstrated therapeutic efficacy in hematologic malignancies and showed growing potential in ...
Veronica Shepeleva
core  

Phagocytosis activity is retained by JMML macrophages and increased by CD47 inhibition

open access: yesBritish Journal of Haematology, EarlyView.
Summary Juvenile myelomonocytic leukaemia (JMML) is a childhood myeloid malignancy driven by RAS (rat sarcoma viral oncogene homolog) pathway mutations, characterized by myeloid cell accumulation and organ infiltration. We investigated how clonal macrophage polarization, phagocytic function and CD47 (cluster of differentiation 47) expression contribute
Jun Wang   +11 more
wiley   +1 more source

TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2013
Patients with ≥ 20% 30% BM blast AML. In the present review, we will discuss the clinical results achieved in the treatment of elderly patients with 20%-30% BM blasts AML using intensive chemotherapy (IC) or hypomethylating agents.
Luca Maurillo   +12 more
doaj   +1 more source

Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents

open access: yes, 2023
Pulmonary infections (PIs) are a major complication of Acute Myeloid Leukemia (AML) treated with hypomethylating agents (HMA). We retrospectively evaluated 147 AML patients treated frontline with HMA in 2 Centers.
De Angelis, Gioia   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy